



Media Kit 2017

GI Dynamics®, Inc.



Contents

- **Company Overview**
- **Our Mission**
- **Opportunity Summary**
- **External Highlights**
- **Success Stories**
- **Press Releases**
- **Financials**


Company Overview

Company

GI Dynamics is the developer of EndoBarrier®, the first endoscopically delivered device therapy approved for the treatment of type 2 diabetes and obesity. Endobarrier is approved in 14 countries outside the United States and commercially available in Europe and the Middle East. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information, please visit www.gidynamics.com.

Product

The EndoBarrier is a thin flexible sleeve that is placed inside your intestine (below your stomach) creating a physical barrier between the intestinal wall and the food you eat. The liner is flexible and moves with your body after placement. There are no incisions needed in the placement or removal of the EndoBarrier.



Product Benefits

- Reduces HbA1c glycemic levels
- Reduces weight
- Reduction in associated health problems due to high blood sugar, obesity, and insulin use.
- Reversible 12 month implant
- Improves long term health and cardiac risk



Management Team

GI Dynamics is led by a team of business, technology experts and medical device industry veterans with a successful track record of leading turnarounds and commercializing important, novel healthcare technologies.



Scott Schorer

President & Chief Executive Officer

Scott brings nearly 20 years of executive experience in the medical device industry, having both founded and helmed numerous companies in the healthcare space.

Brian Callahan

Chief Compliance Officer, Executive Vice President Clinical, Regulatory and Quality

Brian is an accomplished senior compliance executive with more than 25 years of experience in the medical device, pharmaceutical and biologics industries.

Jim Murphy

Chief Financial Officer

Jim Murphy is an accomplished senior finance executive with more than 30 years of experience in high-growth domestic and international environments and extensive experience in the life science sector.

Karl Blohm, Ph.D.

Vice President, International


Karl is a seasoned strategic commercial executive and general manager with more than 20 years of medical device industry experience combining capital equipment and medical devices in both large and small company environments.

Our Mission: to alleviate the symptoms of type 2 diabetes for patients worldwide with a minimally invasive and reversible implant.



- Unique implant for treating the large unmet need of **type 2 diabetes and obesity**
- **Significant efficacy** in glucose control, weight loss and other risk factors
- **Less invasive** therapy with advantageous cost-benefit profile
- Substantial commercial & clinical experience > **3,700 shipped**
- **New team rebuilding confidence**

Substantial Worldwide Clinical Data



Accolades

Recognized in the German Journal of Gastroenterology

Position Paper of Scientific Societies for Recommended Usage of Endoscopic Biliodigestive Diversion in Germany

- German Diabetes Association (“DDG”)
- German Society for General and Visceral Surgery (“DGAV”)
- German Society for Digestive and Metabolic Diseases (“DGVS”)



Case Study Videos



BBC News item

EndoBarrier treatment for diabetes & obesity following 1 year results of ABCD study



ABCD EndoBarrier Study

1-year results, including 10-year CV Risk assessment - Dr Bob Ryder, 2016



BBC News item

EndoBarrier treatment for Obstructive Sleep Apnoea – 2nd ABCD EndoBarrier study

Success Stories

Discover more about our patient success and view videos at: success.gidynamics.com

Before		12 Months After	
HbA1c 109 mmol/mol (12.1%)		HbA1c 58 mmol/mol (7.5%)	
Weight 136.9 kg		Weight 115.0 kg	
BMI 44.7 kg/m ²		BMI 37.6 kg/m ²	
Net Results 4.6% HbA1c 21.9 kg (48.2 lbs) 7.1 BMI			

Before		12 Months After	
HbA1c 77 mmol/mol (9.2%)		HbA1c 40 mmol/mol (5.8%)	
Weight 105.6 kg		Weight 80.0 kg	
BMI 35.3 kg/m ²		BMI 26.7 kg/m ²	
Insulin 100 units		Insulin 0 units	
Net Results 3.4% HbA1c 25.6 kg (56.4 lbs) 8.6 BMI			

Before		12 Months After	
HbA1c 70 mmol/mol (8.6%)		HbA1c 51 mmol/mol (6.8%)	
Weight 82.9 kg		Weight 62.2 kg	
BMI 33.6 kg/m ²		BMI 24.7 kg/m ²	
Net Results 1.8% HbA1c 20.7 kg (45.6 lbs) Normal BMI			

Before		12 Months After	
HbA1c 76 mmol/mol (9.1%)		HbA1c 49 mmol/mol (6.6%)	
Weight 116.4 kg		Weight 88 kg	
BMI 38.0 kg/m ²		BMI 28.8 kg/m ²	
Insulin 42 units		Insulin 0 units	
Related Ambulatory O2		Related No O2	
Net Results 2.5% HbA1c 28.4 kg (62.6 lbs) 9.2 BMI			

Before		12 Months After	
HbA1c 128 mmol/mol (13.9%)		HbA1c 49 mmol/mol (6.6%)	
Weight 102 kg		Weight 64.2 kg	
BMI 39.3 kg/m ²		BMI 24.46 kg/m ²	
Insulin 260 units		Insulin 0 units	
Net Results 7.3% HbA1c 37.8 kg (83.3 lbs) Normal BMI No Insulin			



Clinical Press Releases

Boston, Massachusetts,
United States, and
Sydney, Australia —
AEDT

15 February 2017 | **EndoBarrier® Study in Morbidly Obese Adolescents Completes Enrollment**

GI Dynamics, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier in Europe for patients with type 2 diabetes and obesity, today announced that enrollment is complete in the first clinical trial evaluating EndoBarrier in adolescents. The study was conducted at the University Children's Hospital (UCH) in Ljubljana, Slovenia. [Link](#)

31 January 2017 | **EndoBarrier® Receives German NUB Reimbursement Status 1 for Type 2 Diabetes and Obesity Therapy**

German hospitals have made significant legal progress against resistance to EndoBarrier® reimbursement. Recent court decisions reinforce the assertion that payers must support NUB1 new technology payments for EndoBarrier procedures. [Link](#)

22 November 2016 | **EndoBarrier® Makes Advancement Toward German Reimbursement**

German hospitals have made significant legal progress against resistance to EndoBarrier® reimbursement. Recent court decisions reinforce the assertion that payers must support NUB1 new technology payments for EndoBarrier procedures. [Link](#)

8 November 2016 | **German Registry Releases Positive EndoBarrier® Data at EASD**

The German EndoBarrier registry, which is run at the University Hospital Hamburg-Eppendorf (UKE), recently released positive data at the EASD (European Association for the Study of Diabetes). Dr Nina Riedel of UKE presented data from 234 patients at the EASD in Munich, Germany. [Link](#)

23 June 2016 | **Final Efficacy and Safety Results of U.S. ENDO Trial Announced at ADA**

The ENDO Trial demonstrated clinically meaningful improvements in hemoglobin A1c (HbA1c) levels and weight reduction compared with the sham-treated group. These efficacy outcomes were achieved with only 325[1] of the planned 500 subjects being randomized into the trial. The overall safety profile was positive except for the higher than anticipated rate of hepatic abscess (HA). Of note, no adverse events led to long-term sequelae or mortality. [Link](#)

13 June 2016 | **Results of EndoBarrier Therapy Studies Presented at Digestive Disease Week Meeting**

- EndoBarrier mechanism-of-action study shows ~18 kg mean weight loss and negative correlation between fat absorption and weight loss
- EndoBarrier treatment shows reduction in hepatic fat of 81% and 6x liraglutide effect, an initial indication that EndoBarrier may reduce hepatic fat [Link](#)

**Investor Relations
United States:**
Monica Bellevue
Tel: 781-357-3246



Corporate Press Releases

Boston, Massachusetts,
United States, and
Sydney, Australia —
AEDT

7 May 2017 | **GI Dynamics Announces Scientific Advisory Board Members to Further Development of EndoBarrier**

BOSTON and SYDNEY — 8 May 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, has announced additional members of the GI Dynamics Scientific Advisory Board (SAB), bringing together distinguished physicians and scientists specializing in endocrinology, gastroenterology and bariatric/metabolic surgery. Ricardo Cohen, MD, and Christopher Thompson, MD, MHES, have joined the GI Dynamics SAB. [Link](#)

3 May 2017 | **GI Dynamics Announces EndoBarrier Data to be Presented at Digestive Disease Week**

BOSTON and SYDNEY — 4 May 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced that new EndoBarrier data will be presented at Digestive Disease Week® (DDW), taking place May 6 – 9, 2017 in Chicago, Illinois. [Link](#)

2 May 2017 | **GI Dynamics Selects Allenby Capital to Explore AIM Listing Option**

BOSTON and SYDNEY — 3 May 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces Allenby Capital Limited's engagement to explore options for seeking admission of GI Dynamics shares to trade on the London Stock Exchange's AIM market. [Link](#)

12 March 2017 | **GI Dynamics Announces Scientific Advisory Board Members to Further Scientific Understanding of EndoBarrier**

GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced additional members of the GI Dynamics Scientific Advisory Board (SAB), bringing together distinguished physicians and scientists specializing in endocrinology, gastroenterology and bariatric/metabolic surgery. Manoel Galvao Neto, MD, and David E. Cummings, MD, have joined the GI Dynamics SAB. [Link](#)

6 March 2017 | **GI Dynamics Announces New Scientific Advisory Board and Board's First Two Members**

GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced the creation of the GI Dynamics Scientific Advisory Board (SAB). [Link](#)

Investor Relations
United States:
Monica Bellevue
Tel: 781-357-3246



Financials

Financial Materials

- [Q2 2017 Form 10-K](#)
- [Q3 2016 Appendix 4C](#)
- [Q3 2016 Appendix 10Q](#)
- [Q2 2016 Appendix 10Q](#)
- [Q1 2016 Appendix 4C](#)
- [Q1 2016 Appendix 10Q](#)
- [2015 Form 10-K](#)

Investor Relations

Monica Bellevue
+1 (781) 357-3246
investor@gidynamics.com

Share Registry

Link Market Services Limited
General Shareholder Enquiries:
Phone: 1300 554 474 (toll free) or +61 2 8280 7111
registrars@linkmarketservices.com.au
Fax: +61 2 9287 0303

[Online investor log-in](#)

Locked Bag A14
Sydney South NSW 1235
Australia